Institut Paoli-Calmettes
185
35
46
70
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.4%
10 terminated/withdrawn out of 185 trials
87.5%
+1.0% vs industry average
7%
13 trials in Phase 3/4
1%
1 of 70 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (185)
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
Role: lead
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
Role: lead
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
Role: lead
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
Role: lead
Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer
Role: lead
Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment
Role: lead
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors
Role: lead
Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer
Role: lead
Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
Role: lead
Predictive Clinical and Biological Parameters in Breast Cancer
Role: lead
Therapeutic Nipple Sparing Mastectomy.
Role: collaborator
Predictive Clinical and Biological Parameters in Gynecological Cancer
Role: lead
Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer
Role: lead
Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
Role: lead
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Role: lead
Evaluation of VISIOCYT Bladder Cytology in Real Life
Role: lead
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Role: lead
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
Role: lead
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Role: lead
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
Role: lead